Loading
A phase 1/2 trial of Mosunetuzumab, Tocilizumab, Lenalidomide in follicular lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma is a phase 1/2 interventional study registered as NCT04246086 by Hoffmann-La Roche, with 237 participants planned, started 2020-08-12 and due to reach its primary completion in 2030-09-06. Interventions recorded: Mosunetuzumab (IV), Tocilizumab, Lenalidomide, Mosunetuzumab (SC). Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Shares Mosunetuzumab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Roche / Genentech.
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific).